Agenus Inc. (AGEN) Stock Score, Valuation & Financial Research
Agenus Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 48/100.
Quick answer for AGEN
Agenus Inc. currently has a Wall Street Score of 48/100. The stored market price is $7.13. Its financial score is 0/100. Its valuation score is 100/100. The latest WSS change is +1.6 points. These figures are a research snapshot, not a buy or sell recommendation.
What Agenus Inc. does
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 ant
AGEN financial snapshot
- Wall Street Score:
- 48/100
- Current price:
- $7.13
- Market capitalization:
- $296.9M
- Revenue:
- $132.7M
- Net income:
- $92.0M
- Free cash flow:
- $-158.9M
- Cash:
- $18.7M
- Total debt:
- $40.7M
- EPS:
- 2.72
- P/E ratio:
- 2.6x
- Financial score:
- 0/100
- Valuation score:
- 100/100
- Revenue score:
- 55/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-158.9M, showing cash burn in the current stored period.
- The balance sheet shows $18.7M of cash versus $40.7M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +1.6 points: AGEN increased 1.6 points because Valuation improved by 15 points.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 0/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research AGEN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.